Physician profile
Setare Eslami
NPI 1508399122
$2,279.06
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.77 · 2021: $453 · 2022: $878 · 2023: $509 · 2024: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.91 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $742.31 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $366.71 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $301.10 | 2020-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $152.29 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $121.59 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $103.88 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $101.75 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $90.02 | 2021-2022 | |
| Abbvie INC. | $81.41 | 2024 | |
| Sunovion Pharmaceuticals INC. | $62.16 | 2022 | |
| Nevro Corp. | $48.48 | 2023-2024 | Senza |
| Ironshore Pharmaceuticals INC. | $47.69 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.34 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.89 | 2022 | |
| Tris Pharma INC | $14.44 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Setare Eslami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.